Annual CFI
$1.44 M
-$2.56 M-63.95%
31 December 2023
Summary:
BioLineRx annual cash flow from investing activities is currently $1.44 million, with the most recent change of -$2.56 million (-63.95%) on 31 December 2023. During the last 3 years, it has fallen by -$15.22 million (-91.34%). BLRX annual CFI is now -91.34% below its all-time high of $16.67 million, reached on 31 December 2020.BLRX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$10.18 M
+$18.82 M+217.70%
30 September 2024
Summary:
BioLineRx quarterly cash flow from investing activities is currently $10.18 million, with the most recent change of +$18.82 million (+217.70%) on 30 September 2024. Over the past year, it has increased by +$6.08 million (+148.35%). BLRX quarterly CFI is now -39.02% below its all-time high of $16.69 million, reached on 31 March 2024.BLRX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$2.18 M
+$6.08 M+73.62%
30 September 2024
Summary:
BioLineRx TTM cash flow from investing activities is currently -$2.18 million, with the most recent change of +$6.08 million (+73.62%) on 30 September 2024. Over the past year, it has dropped by -$27.88 million (-108.47%). BLRX TTM CFI is now -108.47% below its all-time high of $25.70 million, reached on 30 September 2023.BLRX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BLRX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -64.0% | +148.3% | -108.5% |
| 3 y3 years | -91.3% | +10000.0% | +93.5% |
| 5 y5 years | -84.9% | +96.1% | +50.2% |
BLRX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -91.3% | +103.8% | -39.0% | +149.9% | -108.5% | +94.3% |
| 5 y | 5 years | -91.3% | +103.8% | -39.0% | +128.1% | -108.5% | +94.3% |
| alltime | all time | -91.3% | +103.8% | -39.0% | +128.1% | -108.5% | +94.3% |
BioLineRx Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $10.18 M(-217.7%) | -$2.18 M(-73.6%) |
| June 2024 | - | -$8.64 M(-151.8%) | -$8.26 M(-171.9%) |
| Mar 2024 | - | $16.69 M(-181.8%) | $11.49 M(+695.6%) |
| Dec 2023 | $1.44 M(-64.0%) | -$20.39 M(-597.8%) | $1.44 M(-94.4%) |
| Sept 2023 | - | $4.10 M(-63.1%) | $25.70 M(+285.4%) |
| June 2023 | - | $11.10 M(+67.1%) | $6.67 M(+19.1%) |
| Mar 2023 | - | $6.64 M(+72.0%) | $5.60 M(+39.8%) |
| Dec 2022 | $4.01 M(-110.5%) | $3.86 M(-125.9%) | $4.01 M(-3.3%) |
| Sept 2022 | - | -$14.94 M(-248.9%) | $4.14 M(-78.3%) |
| June 2022 | - | $10.03 M(+98.7%) | $19.12 M(+519.7%) |
| Mar 2022 | - | $5.05 M(+26.3%) | $3.08 M(-108.1%) |
| Dec 2021 | -$38.22 M(-329.3%) | $4.00 M(+9895.0%) | -$38.22 M(+13.5%) |
| Sept 2021 | - | $40.00 K(-100.7%) | -$33.68 M(+28.7%) |
| June 2021 | - | -$6.00 M(-83.5%) | -$26.18 M(+1.5%) |
| Mar 2021 | - | -$36.26 M(-524.5%) | -$25.78 M(-254.7%) |
| Dec 2020 | $16.67 M(+217.1%) | $8.54 M(+13.3%) | $16.67 M(+47.3%) |
| Sept 2020 | - | $7.54 M(-234.5%) | $11.32 M(+26.3%) |
| June 2020 | - | -$5.61 M(-190.6%) | $8.96 M(-56.8%) |
| Mar 2020 | - | $6.19 M(+94.0%) | $20.76 M(+294.9%) |
| Dec 2019 | $5.26 M(-45.0%) | $3.19 M(-38.5%) | $5.26 M(-220.1%) |
| Sept 2019 | - | $5.19 M(-16.2%) | -$4.38 M(+0.9%) |
| June 2019 | - | $6.19 M(-166.5%) | -$4.34 M(-44.7%) |
| Mar 2019 | - | -$9.31 M(+44.6%) | -$7.84 M(-182.1%) |
| Dec 2018 | $9.55 M(-160.0%) | -$6.44 M(-223.3%) | $9.55 M(-51.3%) |
| Sept 2018 | - | $5.22 M(+94.4%) | $19.60 M(+80.7%) |
| June 2018 | - | $2.69 M(-66.7%) | $10.85 M(-217.8%) |
| Mar 2018 | - | $8.08 M(+124.2%) | -$9.21 M(-42.2%) |
| Dec 2017 | -$15.93 M | $3.60 M(-202.1%) | -$15.93 M(-9.2%) |
| Sept 2017 | - | -$3.53 M(-79.7%) | -$17.55 M(+61.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2017 | - | -$17.37 M(-1370.4%) | -$10.89 M(-220.9%) |
| Mar 2017 | - | $1.37 M(-31.1%) | $9.01 M(-3.1%) |
| Dec 2016 | $9.30 M(-159.6%) | $1.98 M(-36.5%) | $9.30 M(-10.8%) |
| Sept 2016 | - | $3.12 M(+23.2%) | $10.42 M(+61.2%) |
| June 2016 | - | $2.54 M(+53.3%) | $6.46 M(-3.9%) |
| Mar 2016 | - | $1.65 M(-46.7%) | $6.72 M(-143.1%) |
| Dec 2015 | -$15.60 M(-20.9%) | $3.11 M(-472.9%) | -$15.60 M(-31.6%) |
| Sept 2015 | - | -$833.00 K(-129.8%) | -$22.82 M(+3.1%) |
| June 2015 | - | $2.80 M(-113.5%) | -$22.13 M(+3.7%) |
| Mar 2015 | - | -$20.67 M(+403.0%) | -$21.34 M(+8.2%) |
| Dec 2014 | -$19.73 M(+271.0%) | -$4.11 M(+2639.3%) | -$19.73 M(+23.0%) |
| Sept 2014 | - | -$150.00 K(-104.2%) | -$16.04 M(+7.5%) |
| June 2014 | - | $3.59 M(-118.8%) | -$14.92 M(+20.5%) |
| Mar 2014 | - | -$19.06 M(+4486.3%) | -$12.38 M(+132.9%) |
| Dec 2013 | -$5.32 M(-138.7%) | -$415.50 K(-143.0%) | -$5.32 M(-207.0%) |
| Sept 2013 | - | $967.00 K(-84.2%) | $4.97 M(-7.0%) |
| June 2013 | - | $6.12 M(-151.0%) | $5.35 M(-227.7%) |
| Mar 2013 | - | -$11.99 M(-221.4%) | -$4.19 M(-130.5%) |
| Dec 2012 | $13.74 M(-239.3%) | $9.87 M(+635.5%) | $13.74 M(+82.0%) |
| Sept 2012 | - | $1.34 M(-139.3%) | $7.55 M(-3.6%) |
| June 2012 | - | -$3.41 M(-157.5%) | $7.84 M(-20.0%) |
| Mar 2012 | - | $5.94 M(+61.4%) | $9.79 M(-199.2%) |
| Dec 2011 | -$9.87 M(+18.6%) | $3.68 M(+126.1%) | -$9.87 M(-54.7%) |
| Sept 2011 | - | $1.63 M(-211.7%) | -$21.80 M(-5.8%) |
| June 2011 | - | -$1.46 M(-89.4%) | -$23.15 M(+5.3%) |
| Mar 2011 | - | -$13.72 M(+66.2%) | -$21.99 M(+164.2%) |
| Dec 2010 | -$8.32 M | -$8.25 M(-3023.4%) | -$8.32 M(>+9900.0%) |
| Sept 2010 | - | $282.30 K(-194.1%) | -$70.40 K(-80.0%) |
| June 2010 | - | -$299.90 K(+468.0%) | -$352.70 K(+568.0%) |
| Mar 2010 | - | -$52.80 K | -$52.80 K |
FAQ
- What is BioLineRx annual cash flow from investing activities?
- What is the all time high annual CFI for BioLineRx?
- What is BioLineRx annual CFI year-on-year change?
- What is BioLineRx quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for BioLineRx?
- What is BioLineRx quarterly CFI year-on-year change?
- What is BioLineRx TTM cash flow from investing activities?
- What is the all time high TTM CFI for BioLineRx?
- What is BioLineRx TTM CFI year-on-year change?
What is BioLineRx annual cash flow from investing activities?
The current annual CFI of BLRX is $1.44 M
What is the all time high annual CFI for BioLineRx?
BioLineRx all-time high annual cash flow from investing activities is $16.67 M
What is BioLineRx annual CFI year-on-year change?
Over the past year, BLRX annual cash flow from investing activities has changed by -$2.56 M (-63.95%)
What is BioLineRx quarterly cash flow from investing activities?
The current quarterly CFI of BLRX is $10.18 M
What is the all time high quarterly CFI for BioLineRx?
BioLineRx all-time high quarterly cash flow from investing activities is $16.69 M
What is BioLineRx quarterly CFI year-on-year change?
Over the past year, BLRX quarterly cash flow from investing activities has changed by +$6.08 M (+148.35%)
What is BioLineRx TTM cash flow from investing activities?
The current TTM CFI of BLRX is -$2.18 M
What is the all time high TTM CFI for BioLineRx?
BioLineRx all-time high TTM cash flow from investing activities is $25.70 M
What is BioLineRx TTM CFI year-on-year change?
Over the past year, BLRX TTM cash flow from investing activities has changed by -$27.88 M (-108.47%)